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Abstract
Background: Clinical practice guidelines (CPG) are thought to be an effective tool in improving
efficiency and outcomes of clinical practice. Physicians' adherence to guidelines is reported to be
poor. We evaluated the relationship between generalizability of guidelines on hypertension and
physicians' adherence to guidelines' recommendations for pharmacological treatment.
Methods: We used the Sixth Joint National Committee's (JNC VI) guidelines on hypertension to
evaluate our hypothesis. We evaluated the evidence from controlled clinical trials on which the
JNC VI bases its recommendation, and compared the population enrolled in those trials with the
American hypertensive population. Data on this population came from the National Health and
Nutritional Examination Survey III.
Results: Twenty-three percent of the NHANES population had a diagnosis of hypertension, 11%
had hypertension requiring drug treatment according to the JNC VI. Only half of the population
requiring treatment would have been enrolled in at least two trials. Rate of adherence to CPG was
69%. We found a weak association between generalizability and physicians' adherence to guidelines.
Baseline risk was the major determinant of the decision to treat.
Conclusion: JNC VI guidelines may not be generalizable to their target population. We found a
relatively poor adherence rate to these guidelines. Failing of completely taking into account the
clinical characteristics of the patients may be partly responsible for this lack of adherence.
Background
Guidelines are "systematically developed statements to
assist practitioner and patient decisions about appropriate
health care for specific clinical circumstances".[1] Guide-
lines seem to be effective in improving the processes and
outcomes of care, [2] and are being used to describe
appropriate care based on scientific evidence.[3] Another
proposed use of guidelines is for profiling and resource
utilization reviews.[4]
Despite evidence of effectiveness and widespread imple-
mentation efforts, adherence to guidelines is variable and
generally poor.[5–7] The factors involved in a physician's
adherence to guidelines have been extensively studied.
Lack of familiarity and inertia to previous practice, charac-
teristics of the health care professional and of the practice
setting, physician perception of guidelines' usefulness,
incentives, regulation and patient-related factors are com-
mon barriers to guideline adherence.[8–10] The quality of
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the guidelines and the clarity and specificity of their rec-
ommendations seems also to play an important role.[11]
Problems related to the generalizability of clinical practice
guidelines, especially for pharmacological interventions,
have received much less attention in the medical litera-
ture. This could be an issue because intervention guide-
lines should base their recommendations on scientific
evidence from randomized clinical trials.[12] While rand-
omized controlled clinical trials are considered the gold
standard for evaluating the efficacy of pharmacological
interventions, [13] their generalizability is often question-
able, mostly because of stringent inclusion and exclusion
criteria imposed.[14,15] This is particularly true for spe-
cial populations, such as elderly people, who are system-
atically excluded from clinical trials.[16]
We hypothesized that the limited generalizability of the
evidence on which guidelines are based may reduce phy-
sicians' adherence to them. We performed a case study on
guidelines to lower blood pressure to test the hypothesis
that physicians' adherence is lower in groups of people to
whom guidelines are not generalizable.
Methods
Clinical practice guidelines recommendations
For this study, we used the JNC VI guidelines issued by the
National Heart, Blood and Lung Institute, and endorsed
by the American Medical Association along with other 44
US organizations.[17] The contributing team members
reviewed the relevant articles in English language pub-
lished since 1992 to gather scientific evidence. The data
were synthesized into recommendations by consensus of
the executive committee.
The JNC VI categorizes blood pressure levels as optimal
(<120/80 mmHg), normal (<130/85 mmHg), and high
normal (130–139/85–90 mmHg). Hypertension is classi-
fied as stage 1 (140–159/90–99 mmHg), stage 2 (160–
179/100–109 mmHg) or stage 3 (≥ 180/≥ 110 mmHg).
The recommendations for treatment are based on both
hypertension stage and risk for category, and are reported
in table 1.
Conceptual definition of the study population
The population of this study is composed of people who
should be receiving drug treatment according to the
guidelines of the JNC VI (see Table 1). For the analysis of
the characteristics of people with or without a prescription
of an anti-hypertensive drug, we also required that a phy-
sician diagnosed the hypertension.
Operational definition of the study population
Information on the US hypertensive population was
obtained from the National Health and Nutrition Exami-
nation Survey III (NHANES III). This study was designed
to provide national estimates of health and nutritional
estimates of health status of the community-dwelling
population of the United States. Eighty-nine survey loca-
tions were randomly divided into two sets, that were allo-
cated to different study period. To obtain reliable
estimates of health statistics in ethnic minorities as well as
on extreme age groups (children and elderly), these
groups were oversampled. NHANES includes data on
33,994 persons aged 2 months or older. For the present
study, we considered only the adult population (age ≥ 17
years). All participants had blood pressure measurements
obtained during the household interview and during the
examination visit using a mercury sphygmomanometer
according to the standardized protocol recommended by
Table 1: Recommendation of the JNC VI according to blood pressure and presence of additional risk factors.[17]
Blood pressure* Recommendation
High normal
Group risk** A Lifestyle modification
Group risk B Lifestyle modification
Group risk C Drug therapy
Stage 1
Group risk A Lifestyle modification (up to 12 months)
Group risk B Lifestyle modification (up to 6 months)
Group risk C Drug therapy
Stage 2/3
Group risk A Drug therapy
Group risk B Drug therapy
Group risk C Drug therapy
* High normal: 130–139/85–89 mmHg. Stage 1: 140–159/90–99 mmHg. Stage 2/3: ≥ 160/100. ** Group risk A: no risk factors (smoke, dyslipidemia, 
male gender, age ≥ 60 years, family history) or target organ disease (cardiovascular diseases, renal failure) or diabetes mellitus; Group risk B: at least 
one risk factor with no target organ disease or diabetes mellitus; Group risk C: target organ disease or diabetes mellitus.BMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/24
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the American Heart Association, [18] which is similar to
the one recommended by the JNC VI.[19] We used the
mean of three measurements to determine extent of
hypertension. Because of the variable time between the
household interview and the examination visit, we only
considered the blood pressure measurements taken dur-
ing the household interview.
We could not establish from the NHANES data the length
of time lifestyle modification (diet, exercise) had been
tried. Therefore, we decided to focus only on people for
whom the JNC VI suggest drug therapy as a first option
(people with cardiovascular diseases or target-organ dam-
age or diabetes mellitus, or people with stage 2 or stage 3
hypertension). To identify such people, we used the blood
pressure measurements (average of three measurements),
self-reported history of cardiovascular disease or diabetes,
and the measurement of serum creatinine (>2 mg/dl)
indicating impaired renal function. Our definition does
not take into account those with a diagnosis of hyperten-
sion but with normal blood pressure levels. We decided to
exclude these people from our population because we
were unable to evaluate if the prescription was in line with
the JNC VI indications in the absence of an uncontrolled
blood pressure measurement.
Conceptual definition of generalizability
Generalizability is defined as the extent to which the find-
ings obtained on a specific sample can be applied to the
target population.[20] This definition does not imply that
all the characteristics of the sample should be similar to
those of the target population, although it is intuitive that
lack of representativeness in the study sample affects gen-
eralizability. Since the objective of the study was to ana-
lyze the effects of generalizability on adherence to
guidelines, we decided to focus on the demographic and
clinical characteristics that are most likely to influence the
decision to treat, that in our specific case are those related
to the risk/benefit ratio of using anti-hypertensive drugs.
We compared the population that was included in the tri-
als on which the JNC VI recommendations are based with
the US hypertensive population. We only considered con-
trolled clinical trials because recommendations were
mostly based on the evidence from these studies and from
meta-analyses of these studies. To evaluate the generaliza-
bility, we used the following criteria for eligibility in the
trials: age, gender, and blood pressure levels at the
moment of the admission in the study. The exclusion cri-
teria considered were history of myocardial infarction
(MI), heart failure (HF), stroke, and renal impairment
because these target organ diseases increase the risk of
poor outcomes in hypertensive people and are frequently
used as inclusion/exclusion criteria in clinical trials. In
some instances, it was not clear from the methods section
of the trials if the presence of one of these diagnoses
resulted in the exclusion from the study. In these cases, we
used a conservative approach and the variable was not
considered as exclusion criteria (Table 2).
Operational definition of generalizability
According to the JNC VI, diuretics and beta-blockers
should be used as first line pharmacologic therapy to treat
Table 2: Trials on diuretics and/or β-blockers on which the recommendation of the JNC VI are based.
Eligibility criteria Exclusion criteria*
Age (years) Gender Blood pressure** (mmHg) Myocardial 
infarction
Stroke Heart failure Renal 
impairment
VA-NHBLI [36] 35 – 55 Males DBP: 85–105 Excluded Excluded Excluded Excluded
HDPF [37] 30 – 69 Both DBP ≥ 90 Included Included Included Included
Oslo [45] 40 – 50 Male SBP: 145–180 DBP<110 Excluded Excluded Excluded Excluded
Australia [43] 30 – 70 Both DBP: 95–110 SBP<200 Excluded Excluded Included Included
MRC [40] 35 – 64 Both DBP: 90–109 Included Included Included Included
VA I [34] < 70 Male DBP: 115–129 Included Included Included Included
VA II [35] < 70 Male DBP: 90–114 Included Included Included Included
PHS [44] < 55 Both DBP: 90–114 Excluded Excluded Excluded Excluded
HSCSG [33] < 75 Both SBP: 140–220 DBP: 90–115 Included Included Included Excluded
Barraclough [32] 56 – 69 Both DBP: 100–120 Included Included Included Included
Carter [38]<  8 0B o t h B P ≥ 160/110 Included Must have one in 
the previous 3 
months
Excluded Excluded
EWPHE [39] ≥ 60 Both DBP: 90–119 SBP: 160–239 Included Included Excluded Excluded
Coope [42] 60 – 79 Both DBP≥ 105 SBP≥ 170 Excluded Excluded Excluded Excluded
MRC – O [29] 65 – 75 Both DBP<115 SBP: 160–209 Included Included Excluded Excluded
SHEP [41] ≥ 60 Both DBP<90 SBP: 160–219 Excluded Excluded Excluded Excluded
STOP [30] 70 – 84 Both DBP: 90–120 SBP: 180–130 Included Included Included Included
* We considered only these exclusion criteria because they are the most important factors influencing the base line risk in hypertensive people ** 
SPB: Systolic Blood Pressure; DBP: Diastolic Blood PressureBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/24
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hypertension.[17] We identified the clinical trials on
which this recommendation was made. First, we calcu-
lated the proportion of hypertensive people in the
NHANES population that would have been eligible for
the trial on the basis of their age, gender and blood pres-
sure measurements. Second, we calculated the proportion
of people that would have been excluded because of a his-
tory of MI, stroke, HF or renal failure. Third, we calculated
the resulting proportion of people to which the trial is
generalizable. Finally, we calculated the proportion of
people to which the results of at least two trials were gen-
eralizable. We decided to use two trials because we felt
that the results of only one trial were not sufficient to eval-
uate the effects of a treatment. This is also in line with
Food and Drugs Administration's regulation requiring the
evidence from at least two randomized clinical trials to
establish a drug's efficacy.
Conceptual definition of adherence to guidelines
We considered the prescription of any anti-hypertensive
medication as an indicator of physician's adherence to
guidelines. Although the JNC VI indicates diuretics and β-
blockers as first line therapy, we decided to include all the
prescriptions in our definition because different drugs are
allowed or even suggested in particular situations.
Operational definition of adherence to guidelines
To exclude people that had unrecognized hypertension,
we calculated an adherence rate only in those people who
were told by their doctor that they were hypertensive. We
used the self-reported prescription of an anti-hypertensive
medication to measure the physicians' adherence to
guidelines. This approach was chosen instead of using the
actual use of antihypertensive medications to avoid the
confounding effect due to participants' lack of compliance
to medical directives.
Analytic plan
We calculated the proportion of people to which each trial
was generalizable, as well as the proportion of people that
would have been included in at least two trials. We esti-
mated the rate of adherence to guidelines, and compared
the socio-demographic (age, gender, ethnicity) and clini-
cal (diagnosis of MI, angina, HF, stroke, diabetes, renal
impairment, chronic obstructive pulmonary disease)
characteristics of people according to whether they were
in the group for which the guidelines were followed or
not. We also estimated the association of generalizability
with adherence to guidelines using an odds ratio (OR). A
multiple logistic regression model provided an estimate of
the association between generalizability and adherence
corrected for demographic and clinical variables.
We evaluated the rate of adherence to guidelines in each
of the different risk categories identified by the JNC VI
(Table 1) as requiring anti-hypertensive drugs. The risk
factors taken into account to assign people to each risk
category were gender (male), age ≥ 60 years, current smok-
ing, parent with cardiovascular disease before the age of
50, self-reported diagnosis of hypercholesterolemia, and
diabetes mellitus or target organ disease.
Among people that had a prescription of an anti-hyper-
tensive medication and that were actually taking a drug,
we analyzed the prevalence of use of diuretics, β-blockers,
ACE-inhibitors, calcium antagonists, and α-blockers. We
evaluated the use of these drugs both in combination and
used as mono-therapy.
The data reported are weighted proportions using the
applicable weights.[21] The calculation of the standard
errors was performed taking into account the non-ran-
dom sampling strategy of NHANES III. All analyses were
performed using SAS™ Version 8 (SAS Inc., Cary NC) and
SUDAAN™ Version 7.5.6 (RTI, Research Triangle Park,
NC).
Results
The JNC VI recommends the use of diuretics or β-blockers
as first line therapy in hypertension on the basis of the
results of two meta-analyses.[22,23] We found some dif-
ferences in the studies included in these meta-analyses:
Psaty et al. did not include some of the studies that were
used by MacMahon et al., because of the use of multiple
interventions, [24] the use of drugs different than diuretic
of β-blockers, [25,26] or because the study directly com-
pared diuretics to β-blockers.[27] Furthermore, Psaty et al.
included 3 studies that had not been published at the time
when MacMahon et al. published their results.[28–30]
For these reasons, we used the trials included in the meta-
analysis by Psaty et al. We were unable to retrieve informa-
tion from a small study (n = 91) performed in Japan [31]
that was used by Psaty et al. The final number of studies
considered was 16.[29,30,32–45]
Table 2 shows the inclusion and exclusion criteria in the
trials considered. While most trials had advanced age as
exclusion criteria, seven enrolled people aged > 70 years.
The majority of these trials included people with diastolic
hypertension, typically with diastolic blood pressure
around 90 – 120 mmHg. Myocardial infarction was an
exclusion criterion in 6 trials, stroke in 6 trials, HF in 8 tri-
als, and renal failure in 9 trials.
The Adult Survey section of the NHANES III had informa-
tion on 20,050 participants. About 23% of this popula-
tion had a diagnosis of hypertension, and of these 11%
had hypertension requiring treatment according to the
recommendations of the JNC VI. The proportion of peo-
ple with a diagnosis of hypertension but not included inBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/24
Page 5 of 11
(page number not for citation purposes)
our population because they had normal blood pressure
was 17%. In this subgroup of people, 62% reported a pre-
scription of an anti-hypertensive medication. In our study
population, 4.1% had stage 2/3 hypertension with no
other risk factors; 39.2% had stage 2/3 hypertension with
at least one risk factor, 17.3% had high normal blood
pressure and target organ damage or diabetes, 26.1% had
stage 1 hypertension with target organ damage or diabe-
tes, and 13.3% had stage 2/3 hypertension with target
organ diseases or diabetes. The mean age was 63 years
(range 17 – 90), 50% were women and 82% were white.
Table 3 shows the proportion of the people with hyper-
tension requiring drug treatment according to the JNC VI.
The first column reports the percent of the total hyperten-
sive population that would be eligible for each trial
according to their age, gender and blood pressure levels.
The second column reports the proportion of people that
would have been excluded from the trials because of MI,
stroke, HF, and renal impairment. Finally, we report the
proportion of the hypertensive population that would
potentially be enrolled in each trial. We observe a marked
variability in the generalizability of the trials, ranging
from 0.4% (VA I) to 33% (EWPHE). Only four trials were
generalizable to more than 20% of the hypertensive pop-
ulation. Such poor generalizability appeared to be a func-
tion of the eligibility rather than of the exclusion criteria.
Most people were not eligible because high levels of
diastolic blood pressure that were required to be enrolled
in the trials, as well as of age limits for inclusion in the tri-
als. Overall, the proportion of people in our sample that
would potentially have been enrolled in at least 1 trial was
57.5%, and 52.5% would potentially be enrolled in at
least 2 trials.
About 60% of hypertensive people requiring drug treat-
ment according to the JNC VI had been told by a doctor
that they had hypertension. Of these, 69% reported hav-
ing a current prescription for anti-hypertensive drugs.
Table 4 compares the characteristics of people reporting a
prescription for anti-hypertensive drugs vs. those not
reporting a prescription for an antihypertensive medica-
tion. People in the first group were more likely to be eld-
erly (42.3% treated vs. 16.4% not treated). Fifty-six
percent of diagnosed hypertensives who were treated were
women compared to 43.2% who were not treated. The
distribution of race/ethnicity varied slightly according to
treatment with a lower prevalence of whites among the
treated group (81.5% vs. 85.5% not treated). Stroke, HF
and renal failure were associated with more than a dou-
bling of the probability of having a prescription for anti-
hypertensive drugs. The prevalence of MI was 23% among
those with prescription, and 15.5% among those without
a prescription. Diabetes (28.8% vs. 25.9%) and chronic
obstructive pulmonary disease (16.2% vs. 13.4%) were
not associated with treatment. We observed a lower prev-
alence of people that would have been enrolled in at least
two trials in the group receiving drug treatment. People
similar to the population enrolled in clinical trials were
30% less likely to receive any hypertensive treatment,
although the confidence intervals were wide (OR: 0.7,
95% CI: 0.4 – 1.3).
Table 3: Generalizability of the individual trials to the hypertensive population.
% of the pop. eligible* for trial % of the eligible pop. that would be 
excluded**
% of the pop. to which the trial is 
generalizable
VA-NHBLI [36] 9.7 14.1 8.3
HDPF [37] 28.8 0 28.8
Oslo [45] 3.3 10.6 2.9
Australia [43] 18.1 5.7 17.1
MRC [40] 21.0 0 21.0
VA I [34] 0.4 0 0.4
VA II [35] 18.9 0 18.9
PHS [44] 18.5 9 16.9
HSCSG [33] 1.2 1.1 1.2
Barraclough [32] 11.0 0 11.0
Carter [38] 2.6 25 1.8
EWPHE [39] 37.4 22.3 32.8
Coope [42] 14.2 22.1 11.1
MRC – O [29] 14.8 9.7 13.2
SHEP [41] 22.0 26.5 16.2
STOP [30] 2.1 3.2 2.1
* Eligibility criteria shown in table 2. People with hypertension and controlled blood pressure was excluded from the analysis. ** Exclusion criteria 
shown in table 2.BMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/24
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After adjustment for demographic and clinical characteris-
tics, the direction of the association between generaliza-
bility and treatment was reversed, with people similar to
those included in clinical trial being 20% as likely to
receive an antihypertensive medication than those with-
out such characteristics (OR: 1.2; 95% CI: 0.6 – 2.8). The
estimated association for the other variables was
unchanged, except for physical impairment, which after
the adjustment was associated with a decreased probabil-
ity of being prescribed an antihypertensive drug.
Figure 1 shows the rate of adherence to guidelines among
the group to which the trials were generalizable compared
to those to whom the trials were not generalizable. Adher-
ence to guidelines was in general higher in the groups
with target organ diseases or diabetes mellitus. In the
group with high normal blood pressure and target organ
disease, we found nobody that would have been included
in at least two trials. In the other groups, generalizability
had little effect on the adherence rate. People in the group
to which the trials can be generalizable had a lower prev-
alence of treatment, although the differences were small.
An exception was the group with stage 2/3 hypertension
and at least 1 risk factor, in which people that would have
been enrolled in at least two trials were more likely to be
treated (81% vs. 75%).
Of hypertensive people who had both a diagnosis and a
prescription made by their physician, 76% were actually
taking any medication at the time of the interview. Table
5 shows the type of treatment reported. When we consid-
ered only drugs used in mono-therapy, we found that cal-
cium channel blockers were the drugs most frequently
used (15%), followed by diuretics and ACE-inhibitors
(11%). β-blockers were taken as mono-therapy by 9% of
persons. Considering any prescription, diuretics were the
drugs most commonly used (41.5%), followed by cal-
cium channel blockers (38.8%) and ACE-inhibitors
(31.6%), and β-blockers (26.1%).
Discussion
The JNC VI bases its recommendations on the drug treat-
ment of hypertensive people on a convincing scientific
basis. The pooled results of the trials on diuretics and/or
β-blockers considered as the basis for the guidelines show
a clear reduction in stroke, [22,46] congestive HF and
total cardiovascular mortality.[22,23,46] Nonetheless,
differences between the populations studied and the pop-
ulations actually receiving the medications pose the prob-
lem of the generalizability of the results. Using only few
eligibility/exclusion criteria, we found that the generaliza-
bility of the individual trials was poor. Forty percent of the
population would not have been enrolled in at least one
trial, and half of the population was not eligible for at
least two trials.
The JNC VI extends its recommendation to people with
blood pressure levels generally lower than the population
included in the trials. In one of the groups for which
treatment is recommended by the JNC VI (i.e. people with
high normal blood pressure and target-organ disease or
diabetes), we found nobody that would be included in at
least two trials. This is problematic. Since characteristics of
the population translate into different baseline risks, the
absolute benefits observed in trials may be different than
those observed in the general population.[47] While it is
arguable that clinical trials, excluding people with sub-
stantial comorbidity, underestimate the real benefit of the
Table 4: Comparison of the characteristics of people with diagnosed hypertension who were told to take antihypertensive medications 
vs. people not told.
Treatment prescribed % Treatment not prescribed % Odds Ratio (95% C. I.) Adjusted Odds Ratio 
(95% C. I.)
Age ≥ 70 years 42.3 16.4 3.8 (2.6 – 5.4) 4.1 (2.9 – 6.0)
Women 55.8 43.2 1.7 (1.1 – 2.5) 1.5 (1.0 – 2.5)
Race / Ethnicity
White 81.5 85.5 1.0 1.0
Black 16.3 12.0 1.4 (0.9 – 2.2) 1.7 (1.1 – 2.6)
Other 2.1 2.2 1.0 (0.2 – 4.3) 0.9 (0.2 – 4.1)
Myocardial infarction 23.0 15.5 1.6 (1.0 – 2.8) 1.5 (0.9 – 2.7)
Stroke 13.1 6.0 2.3 (1.3 – 4.20) 1.9 (0.9 – 4.1)
Heart failure 16.3 8.3 2.2 (1.1 – 4.2) 2.1 (0.8 – 5.5)
Renal impairment 4.8 1.7 3.0 (0.7 – 13.6) 2.5 (0.4 – 14.6)
Diabetes 28.9 25.9 1.2 (0.7 – 1.9) 1.4 (0.8 – 2.5)
Chronic pulmonary disease 13.4 16.2 0.8 (0.4 – 1.6) 0.7 (0.3 – 1.1)
Physical impairment 13.3 11.6 1.2 (0.7 – 2.1) 0.6 (0.3 – 1.1)
Eligible in 2 or more trials 53.3 62.4 0.7 (0.4 – 1.3) 1.2 (0.6 – 2.8)BMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/24
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Proportion of people receiving drug treatment according to trials' generalizability Figure 1
Proportion of people receiving drug treatment according to trials' generalizability. Stratified by blood pressure and risk cate-
gory as defined in table 1.
Table 5: Use of anti-hypertensive drugs among people who had a medication prescribed by their doctors and that were taking the drug 
at the time of the interview.
Monotherapy
Diuretics 11.2
β-blockers 9.1
ACE-inhibitors 10.9
Calcium antagonists 14.9
Alpha adrenergic / alpha blockers 3.7
Treatment taken alone or in combination
Diuretics 41.5
β-blockers 26.1
ACE-inhibitors 31.6
Calcium antagonists 38.8
Alpha adrenergic / alpha blockers 10.2
0%
20%
40%
60%
80%
100%
Stage 2-3 /
Group A
Stage 2-3 /
Group B
High Normal
/ Group C
Stage 1 /
Group C
Stage 2-3 /
Group C
Trials generalizable Trials not generalizable TotalBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/24
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treatment, [48] any generalization to a population with a
baseline risk level different the one studied in an individ-
ual trial needs to be evaluated. Furthermore, since the risk
of adverse drug reactions increases with the underlying
clinical severity, [49] it is seldom easy to estimate the real
risk/benefit ratio when data are not available in a specific
population.
Our data show that a substantial proportion of people
(30%) with a diagnosis of hypertension and that should
receive treatment according to the JNC VI guidelines have
not been prescribed any antihypertensive drug. Our
results are in line with another report from NHANES III
showing that about 50% of all people with a diagnosis of
hypertension (regardless of the actual blood pressure)
were not receiving treatment.[50]
The decision not to treat might be a due to poor familiar-
ity with the JNC guidelines, [51] to a risk/benefit
evaluation tailored to the individual patient, or to patient
preference.[52] Our data show that the risk profile is
much more important in influencing treatment than the
actual blood pressure levels. In fact, people with stage 2/3
hypertension but without risk factors or target-organ dis-
ease were treated less frequently than people with lower
blood pressure with additional risk factors or target-organ
diseases. The higher prevalence of treatment in people at
higher risk (advanced age, cardiovascular diseases, and
diabetes mellitus) suggests that the characteristics of the
individual patient are a major determinant of the decision
to treat. Although this finding might be an artefact due to
the fact that people receiving treatment for hypertension
are likely to have normal blood pressure levels and there-
fore not captured by our study, other data from different
settings support this interpretation. A community-based
study in a older population showed that hypertensive
people with additional risk factors were more likely to
receive antihypertensive medications, [53] while a pro-
spective study in a family medicine setting found that
treatment for hypertension was independent from the
actual blood pressure readings.[54] Concomitant
cardiovascular diseases were associated with increased use
of antihypertensive in a nursing home population.[55]
The explanation that physician's own clinical judgment
might override guidelines' recommendation is also in
accordance with data on compliance with guidelines on
diabetes care.[56]
We found that, among people with a prescription and tak-
ing an antihypertensive drug at the time of the interview,
the type of medication was not following the indication of
the JNC VI. This failure of the JNC guidelines in influenc-
ing the type of therapy described has already been
described in a study examining the effect of the fifth report
of the JNC.[57] However, it must be noted that this is a
cross-sectional study and we have no information on
which drugs have previously been tried.
Our data show no association between the generalizabil-
ity of the trials and the decision to prescribe an antihyper-
tensive medication. This study is underpowered to rule
out an association, but the comparison of the point esti-
mates of the OR of being treated in the crude analysis and
the adjusted model confirms the role of the clinical char-
acteristics in physicians' adherence. In the crude analysis,
where this baseline risk is not taken into account, people
to whom the clinical trials are not generalizable are more
likely to be treated. In the multivariable analysis taking
into account the baseline risk, the direction of the associ-
ation is reversed. The reason for this finding probably lies
in the fact that clinical trials considered tend to exclude
high risk people (see table 2), who are the most likely ben-
efit from treatment and therefore to be treated in clinical
practice.
Translating trial findings into clinical decision making is
never an easy task, and generalizability is one of the fac-
tors that should be taken into account when trying to
implement "evidence based" interventions. Other related
factors are also likely to play a role. Patient's preference is
one of these, and has more far-reaching implications than
just treatment choice. The prescription of a drug that the
patient deems effective may have a beneficial effect in and
of itself, something that has been defined "therapeutic
effect of patient preference".[58] While controlled clinical
trials can avoid this problem by blinding the patients to
the treatment they are receiving, in the clinical practice set-
ting this is impossible. Furthermore, patients with strong
preference are likely to refuse randomization, and this
clearly affects generalizability. One possible solution is to
use information coming from settings more similar to the
clinical practice when making recommendations. For
example, beside observational studies, valuable informa-
tion can come from "pragmatic trials", that are performed
in the real clinical practice, and aim to inform choices
between treatments rather than to measure the benefit of
a treatment under ideal circumstances.[59]
Limitations
The results of this study should be evaluated taking into
account the limitations of our approach. First, people
receiving an antihypertensive medication are more likely
to have normal blood pressure, therefore were not in our
sample. Although the proportion of people whose high
blood pressure was controlled by anti-hypertensive drugs
was relatively low (10%), this bias potentially leads to an
underestimation of the adherence to guidelines. However,
the treatment rate in this population (70%) is similar to
that reported in another study in a different setting, inBMC Public Health 2003, 3 http://www.biomedcentral.com/1471-2458/3/24
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which the prevalence of treatment among people with
known hypertension was 80%.[60]
The diagnosis of hypertension and the decision on drug
treatment were made before the blood pressure levels
used in this study were measured. Therefore, the blood
pressure at the time of the last physician's visit was not
necessarily as high as at the moment of the study inter-
view. The result would be an underestimation of the
adherence rate. Although this bias cannot be discounted,
the rate of treatment that we observed is similar to that
observed in other studies.[61,62] Furthermore, blood
pressure was measured at a single point in time, and there
is the possibility that a regression to the mean effect have
reduced the number of patients appropriate for the JNC VI
guidelines. Another source of bias might come from peo-
ple who were prescribed lifestyle modification, and whose
blood pressure had increased to level requiring drug treat-
ment at the time of the interview. Again, we would have
underestimated the adherence rate.
We control only for only a few eligibility/exclusion crite-
ria. It is probable that the proportion of people that would
have been enrolled in the clinical trials we considered is
actually much lower than we report. For example, in the
SHEP trial only 2.7% of people screened were eligible to
the first baseline visit. Of these, less than half was actually
randomized. If people to whom the trials are generaliza-
ble were actually more likely to receive treatment, this
misclassification would result in a spurious negative asso-
ciation between generalizability and treatment. On the
contrary, if people excluded from the trial are more likely
to receive drug treatment, we might underestimate the
negative association between generalizability and adher-
ence to guideline. Data from the literature show that the
second scenario is more likely, with people with risk fac-
tors that lead to exclusion from the clinical trial being
more likely to be treated.
Finally, the precision of our estimates was quite low, and
the inferences that can be made on the basis of our data
are limited by this lack of statistical power.
Conclusion
Guidelines on drug treatment of hypertension are based
on evidence obtained in general on samples that are dif-
ferent from the target population with regard to important
clinical characteristics. These differences may translate in
a different baseline risk profile, and consequently with a
different risk/benefit ratio of antihypertensive therapy.
Our data suggest a weak association between generaliza-
bility and adherence rate, although our findings are not
statistically significant. We found that the individual risk
profile influence role on physicians' decision to treat more
than blood pressure levels. Differences in the risk profile
between people enrolled in the studies on which clinical
practice guidelines and the target population might affect
the adherence rate.
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